Compass Therapeutics, Inc. (CMPX)

1.7000 +0.0500 (+3.03%) At close: 04:00PM EDT

Compass Therapeutics, Inc.

80 Guest Street
Suite 601
Boston, MA 02135
United States
(617) 500-8099
https://www.compasstherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 32

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Vered Bisker-Leib M.D., MBA, Ph.D.	CEO & Director	719k	N/A	1971
Dr. Thomas J. Schuetz M.D., Ph.D.	Co-Founder, President of Research & Development and Vice Chairman of the Board	835.88k	N/A	1961
Mr. Neil L. Lerner CPA	Vice President of Finance	N/A	N/A	1967
Mr. Jonathan Anderman J.D.	VP, Head of Legal & Corporate Secretary	N/A	N/A	N/A
Anna Gifford	Communications Manager	N/A	N/A	N/A
Dr. Minori Rosales M.D., Ph.D.	Senior VP & Head of Clinical Development	N/A	N/A	1963
Ms. Karin Herrera B.A.	VP & Head of Clinical Operations	N/A	N/A	N/A
Dr. James Kranz Ph.D.	VP and Head of Chemistry Manufacturing & Controls	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Corporate Governance

Compass Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.